Jx 594 Clinical Trial

Preventing Postoperative Metastatic Disease By Inhibiting ...
Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells Lee-Hwa Tai 1, In clinical studies, a complicated postop-erative course corrresponds to an increase in physiologic surgical stress. ... Get Doc

Effect Of Aldosterone On The Amplification Of Oncolytic ...
Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines Hyun Ju Lee1*, Jasung Rho1*, Shao Ran Gui2, Mi Kyung Kim2, Yu Kyoung Lee2, Yeon Sook Lee2, clinical trial of JX-594, viral replication of JX-594 was noted in ... View Doc

Systemic Armed Oncolytic And Immunologic Therapy For Cancer ...
Patients on this clinical trial. Intravenous (i.v.) delivery to tumors with HSV and adenoviruses appears to be extremely inefficient, how-ever, due to complement-mediated and reticuloendothe- JX-594 was thawed, sonicated, and then diluted in lactated RingerTs ... View Document

Transgene SA - Wikipedia, The Free Encyclopedia
Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. [1] "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer." ... Read Article

Oncolytic Virotherapy Needs Trials, Not Access Programs
Oncolytic Virotherapy Needs Trials, Not Access Programs (JX-594;JennerexBiotherapeutics)inhepatocellularcancer (6). et al. Phase II clinical trial of a granulocyte-macrophage colony-stim-ulating factor-encoding, ... Retrieve Document

Less Radiotherapy Side-effects Using Oncolytic Viruses? How ...
Less radiotherapy side-effects using oncolytic viruses? How to kill cancer cells. JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. ... View Video

Regional Delivery Of Oncolytic Vaccinia Virus: It’s Time For ...
Regional Delivery of Oncolytic Vaccinia Virus: Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–36. 3. ... Retrieve Here

DECISION - Environmental Protection Authority
Virus (Pexa-Vec) for use in a Phase 3 clinical trial for patients with hepatocellular carcinoma. The new organism approved Pexa-Vec (pexastimogene devacirepvec; JX-594; as described in 1 The Chief Executive of the EPA has made the decision on this application under delegated authority in ... Access Document

JX-594 - Wikipedia, The Free Encyclopedia
JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, Clinical trials (30 patient) phase II trial in advanced hepatocellular carcinoma (HCC) ... Read Article

INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF ...
Trial of JX-594 (Vaccinia GM-CSF This report together with JX-594 pre-clinical data showing INFORMATION REQUIRED IN NOTIFICATIONS CONCERNING RELEASES OF GENETICALLY MODIFIED ORGANISMS OTHER THANT HIGHER PLANTS Author: Sylvia Nangeroni Created Date: ... Retrieve Here

A Media Event On Clinical Developments In Gene And Cell Therapy
A Media Event on Clinical Developments in Gene and Cell Therapy MILWAUKEE (Wednesday, May 2nd, expressing human Factor IX in a clinical trial on hemophilia patients have significantly improved (JX-594) to combine ... Read Content

Immune Play: Defending The Liver - WOMEN IN MEDICINE LTD
Immune play: defending the liver Geraldine O’Sullivan Coyne1 & Tim F Greten*,2 Intrahepatic injection of vaccinia JX-594 was performed in a randomized Phase II dose- dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19(3), ... View This Document

Liu TC - Washington University In St. Louis
Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients ... View Document

Results Of World-first Viral Therapy trial In Ottawa Cancer ...
Results of world-first viral therapy trial in Ottawa cancer patients published in Nature. Researchers from the Ottawa patients received a single intravenous infusion of a virus called JX-594, at one of Patients interested in participating in clinical trials should discuss this with ... View This Document

Oncolytic Immunotherapeutic Virus In HCC: Can It Compete With ...
Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies? Randomized dose-finding clinical trial of oncolytic immuno- JX-594 systemic administration (c linicalTrials.gov, NCT01636284). ... Content Retrieval

Micro-dose Chemo For Cancer Using Oncolytic Viruses. Cancer ...
Micro-dose chemo for cancer using oncolytic viruses. Cancer therapy - future healthcare JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. ... View Video

Dobutamine Stress Mri For The Assessment Of Coronary Artery ...
Dobutamine stress mri for the assessment of coronary artery disease: expanding our Field of view JX-594 (Pexa-Vec) is an oncolytic randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia Jx-594 in liver cancer. ... Fetch Content

Developers Of Oncolytic Virotherapeutics LATEST NEWS For ...
II trial and oncolytic virotherapy has emerged as a real and potent addition to in later stages of clinical development, demonstrate the potential commercial (JX-594) which has demonstrated anti-cancer ... Return Doc

Articles http://oncology.thelancet.com Published online May 19, 2008 Webtable 1 Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver ... Access Doc

COLORECTAL CANCER RESEARCH UPDATES
COLORECTAL CANCER RESEARCH UPDATES Month Ending January 13th, 2012 The following colorectal cancer research update extends from November 19th, Jennerex Announces First Patient Treated in Phase 2a Clinical Trial Involving JX-594 7. Phase 2 Trial Testing Tivozanib in Combination with Folfox6 ... Fetch This Document

Oncolytic Immunotherapy: Using Viruses In The War Against Cancer
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Medicine, 1(3), 329–336. Kelly, E., & Russell, S. (2007). History of oncolytic viruses: Gen- Oncolytic Immunotherapy JX‐594 ... Get Document

The Role Of GM-CSF In Enhancing Immunotherapy Of Cancer
Normally be afforded in a traditional clinical trial [8]. The role of GM‑CSF in enhancing immunotherapy of cancer PRIORITY PAPER EVALUATION immunotherapeutic vaccinia JX‑594 in liver cancer. Nat. Med. 19, 329–336 (2013). ... Retrieve Content

GeMCRIS - Osp.od.nih.gov
GeMCRIS® Genetic Modification Clinical Research Information System. Web-based HGT Resource All clinical trial information is accessed through . JX-594…) Biological Descriptors: • Vector Classes ... Read Here

Oncolytic Vaccinia Virus For The Treatment Of Cancer
Oncolytic vaccinia virus for the treatment of cancer Describes the first JX-594 clinical trial in melanoma patients. 68. Shanafelt AB, Johnson KE, Kastelein RA. Identification of critical amino acid residues in human and mouse granulocyte-macrophage ... View Doc